SUMMIT, N.J., July 30, 2021 /PRNewswire/ — Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), presented findings from a new observational safety study conducted in the U.S. that found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the company’s cell-based quadrivalent seasonal influenza vaccine (QIVc) during pregnancy.1 These data were presented at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Meeting on July 30, 2021.
The prospective observational cohort study evaluated pregnancy outcomes and events of interest in the fetus or infant following vaccination with QIVc during any trimester.1 The findings from this study were reviewed by an independent Scientific Advisory Committee (SAC).1
“Pregnant people and people who have recently given birth can be particularly vulnerable to infectious diseases like influenza,” said Christopher Robinson, MD, MSCR, Charleston Maternal Fetal Medicine and study author. “These data provide further reassurance on the safe use of seasonal influenza vaccines in pregnant people.”
Pregnant people are considered an at-risk population for influenza.2 Changes that occur in the immune system, heart and lungs during pregnancy can make those who are pregnant, and those who are up to two weeks postpartum, more prone to severe illness or complications from influenza.2 Influenza vaccination is the best way to prevent influenza and the Centers for…